From Nasdaq:

The U.S. FDA approves Heron Therapeutics Inc.’s ZYNRELEF to expand its indication for soft tissue and orthopedic surgical procedures, including foot and ankle surgeries. The expanded indication will cover an estimated 13 million procedures annually, an 86% increase over prior indicated procedures. ZYNRELEF is the first therapy for postoperative pain management to demonstrate superiority to bupivacaine solution. The drug was initially approved by the FDA in May 2021 and received approval for an expanded label in December 2021. For more health news, visit rttnews.com.



Read more: Heron : FDA Oks ZYNRELEF Indication Expansion To Include Addl. Orthopedic & Soft Tissue Procedures